Identification of responders and reactive domains to rivastigmine in Alzheimer's disease

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 5, 2007, Pages 545-551

  Frankfort, S V ^a   Appels, B A ^a   de Boer, A ^b   Tulner, L R ^a   van Campen, J P C M ^a   Koks, C H W ^a   Beijnen, J H ^a,b   Schmand, B A ^c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Alzheimer's disease; CAMCOG; Cognitive domains; Responders; Rivastigmine

Indexed keywords

RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LANGUAGE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; PERCEPTION; PRIORITY JOURNAL; THINKING; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249733659     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1345     Document Type: Article

References (37)

1. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
2. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 1999; 318: 633-638.
3. Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology 2001; 20: 51-56.
4. Farlow MR, Lane R, Kudaravalli S, He Y. Differential qualitative responses to rivastigmine in APOE 4 carriers and noncarriers. Pharmacogenomics J 2004; 4: 332-335.
5. Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001; 58: 417-422.
6. Farlow MR, Small GW, Quarg P, Krause A. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord 2005; 20: 192-197.
7. Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien JT. Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry 2003; 18: 879-886.
8. Gauthier S. Cholinergic adverse events of cholinesterase inhibitors in Alzheimer's disease. Epidemiology and management. Drugs Aging 2001; 18: 853-862.
9. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy Bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036.
10. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
11. Walstra GJ, Teunisse S, van Gool WA, van Crevel H. Reversible dementia in elderly patients referred to a memory clinic. J Neurol 1997; 244: 17-22.
12. Verhage F. Intelligence and Age. (in Dutch). van Gorcum: Assen. 1964.
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
14. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to early detection of dementia. Br J Psychiatry 1986; 149: 698-709.
15. Schmand B, Walstra G, Lindeboom J, et al. Early detection of Alzheimer's disease using the Cambridge Cognitive Examination (CAMCOG). Psychol Med 2000; 30: 619-627.
16. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Br Med J 2005; 331: 321-323.
17. Francis PT, Palmer AM, Snape M, Wilcock G. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-147.
18. Sahakian BJ, Coall JT. Nicotine and tetrahydroaminoacradine: evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res 1994; 31: 80-88.
19. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54: 407-411.
20. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-2529.
21. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11: 131-145.
22. Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer's disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 2004; 18: 123-128.
23. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 243-249.
24. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Br Med J 2000; 321: 1445-1449.
25. McLendon B, Murali Doraiswamy P. Defining meaningful change in Alzheimer's disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999; 12: 39-48.
26. NICE 2006/001: NICE consults on revised first draft guidance on the use of drugs to treat Alzheimer's disease. http://www.nice.org.uk/ pdf2006_001_AlzΡess_release_AD_App_Jan06.pdf. Accessed March 28, 2006.
27. Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999; 281: 1401-1406.
28. Perry RJ, Watson P, Hodges JR. The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologica 2000; 38: 252-271.
29. Morris JC, Edland S, Clarck C, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV: rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993; 43: 2457-2465.
30. Stern Y, Liu X, Albert M, et al. Application of a growth curve approach to modeling the progression of Alzheimer's disease. J Gerontol 1996; 51A: M179-M184.
31. Mendiondo MS, Wesson Ashford J, Kryscio RJ, Schmitt FA. Modelling mini-mental state examination changes in Alzheimer's disease. Stat Med 2000; 19: 1607-1616.
32. Garre-Olmo J, López-Pousa S, Vilalta-Franch J, et al. Neuropsychological profile of Alzheimer's disease in women: moderate and moderately severe cognitive decline. Arch Womens Ment Health 2004; 7: 27-36.
33. Cullum S, Huppert FA, McGee M, et al. Decline across different domains of cognitive function in normal ageing: results of a longitudinal population-based study using CAMCOG. Int J Geriatr Psychiatry 2000; 15: 853-862.
34. Lindeboom R, Schmand B, Holman R, et al. Improved brief assessment of cognition in aging and dementia. Neurology 2004; 63: 543-546.
35. Huppert FA, Brayne C, Gill C, et al. CAMCOG--a concise neuropsychological test to assist dementia diagnosis: sociodemographic determinants in an elderly population sample. Br J Clin Psychol 1995; 34: 529-541.
36. Williams JG, Huppert FA, Matthews FE, Nickson J. Performance and normative values of a concise neuropsychological test (CAMCOG) in an elderly population sample. Int J Geriatr Psychiatry 2003; 18: 631-644.
37. Farlow MR, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment. Neurology 2004; 63: 1898-1901.